6:12 PM
 | 
Mar 04, 2013
 |  BC Extra  |  Company News

FDA panel rebuffs two menopause compounds

FDA's Reproductive Health Drugs Advisory Committee voted on Monday that the overall benefit/risk profiles of two compounds do not support approval to treat moderate to severe vasomotor symptoms (VMS)...

Read the full 123 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >